LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 3 | G07 | 72 | hr | 1235 | 332 | 4513 | 0.0736 | -0.2758 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP5 | 1 | F01 | 72 | hr | 1235 | 403 | 4513 | 0.0893 | -0.2541 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP5 | 2 | F01 | 72 | hr | 1235 | 409 | 4513 | 0.0906 | -0.2523 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP5 | 3 | F01 | 72 | hr | 1235 | 552 | 4513 | 0.1223 | -0.2087 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP6 | 1 | G01 | 72 | hr | 1235 | 343 | 4513 | 0.0760 | -0.2724 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP6 | 2 | G01 | 72 | hr | 1235 | 165 | 4513 | 0.0366 | -0.3267 |
| MDA-MB-231 | CGP60474 | 10.0 | uM | LJP6 | 3 | G01 | 72 | hr | 1235 | 514 | 4513 | 0.1139 | -0.2203 |
| MDA-MB-231 | CHIR-99021 | 10.0 | uM | LJP6 | 1 | P13 | 72 | hr | 1235 | 3340 | 4513 | 0.7400 | 0.6419 |
| MDA-MB-231 | CHIR-99021 | 10.0 | uM | LJP6 | 2 | P13 | 72 | hr | 1235 | 3371 | 4513 | 0.7469 | 0.6514 |
| MDA-MB-231 | CHIR-99021 | 10.0 | uM | LJP6 | 3 | P13 | 72 | hr | 1235 | 3788 | 4513 | 0.8392 | 0.7786 |
| MDA-MB-231 | CP724714 | 10.0 | uM | LJP5 | 1 | A07 | 72 | hr | 1235 | 4571 | 4513 | 1.0127 | 1.0175 |
| MDA-MB-231 | CP724714 | 10.0 | uM | LJP5 | 2 | A07 | 72 | hr | 1235 | 4250 | 4513 | 0.9416 | 0.9196 |
| MDA-MB-231 | CP724714 | 10.0 | uM | LJP5 | 3 | A07 | 72 | hr | 1235 | 4151 | 4513 | 0.9197 | 0.8894 |
| MDA-MB-231 | CP466722 | 10.0 | uM | LJP5 | 1 | I07 | 72 | hr | 1235 | 2135 | 4513 | 0.4730 | 0.2743 |
| MDA-MB-231 | CP466722 | 10.0 | uM | LJP5 | 2 | I07 | 72 | hr | 1235 | 2380 | 4513 | 0.5273 | 0.3490 |
| MDA-MB-231 | CP466722 | 10.0 | uM | LJP5 | 3 | I07 | 72 | hr | 1235 | 2210 | 4513 | 0.4896 | 0.2972 |
| MDA-MB-231 | Crizotinib | 10.0 | uM | LJP5 | 1 | A19 | 72 | hr | 1235 | 926 | 4513 | 0.2052 | -0.0946 |
| MDA-MB-231 | Crizotinib | 10.0 | uM | LJP5 | 2 | A19 | 72 | hr | 1235 | 920 | 4513 | 0.2038 | -0.0964 |
| MDA-MB-231 | Crizotinib | 10.0 | uM | LJP5 | 3 | A19 | 72 | hr | 1235 | 971 | 4513 | 0.2151 | -0.0808 |
| MDA-MB-231 | Momelotinib | 10.0 | uM | LJP5 | 1 | P07 | 72 | hr | 1235 | 483 | 4513 | 0.1070 | -0.2297 |
| MDA-MB-231 | Momelotinib | 10.0 | uM | LJP5 | 2 | P07 | 72 | hr | 1235 | 565 | 4513 | 0.1252 | -0.2047 |
| MDA-MB-231 | Momelotinib | 10.0 | uM | LJP5 | 3 | P07 | 72 | hr | 1235 | 675 | 4513 | 0.1496 | -0.1711 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP5 | 1 | D01 | 72 | hr | 1235 | 562 | 4513 | 0.1245 | -0.2056 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP5 | 2 | D01 | 72 | hr | 1235 | 527 | 4513 | 0.1168 | -0.2163 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP5 | 3 | D01 | 72 | hr | 1235 | 827 | 4513 | 0.1832 | -0.1248 |